Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Sulfasalazine
Drug ID BADD_D02093
Description A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see mesalamine) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
Indications and Usage For the treatment of Crohn's disease and rheumatoid arthritis as a second-line agent.
Marketing Status approved
ATC Code A07EC01
DrugBank ID DB00795
KEGG ID D00448
MeSH ID D012460
PubChem ID 5339
TTD Drug ID D02ZTJ
NDC Product Code 63629-5688; 49452-7523; 59116-0631; 0093-3234; 70518-0185; 51552-1044; 51927-0081; 50090-2013; 59762-5000; 62135-960; 70518-1829; 70518-3732; 0013-0102; 71610-577; 62705-0222; 62991-2704; 59762-0104; 70518-2342; 71610-706; 49964-0018; 57294-021; 50090-0086; 51927-0054; 59116-0632; 0591-0796; 23155-019; 0013-0101; 63629-9715; 38779-0176; 59116-0630; 59116-0633; 68022-7065
UNII 3XC8GUZ6CB
Synonyms Sulfasalazine | Salicylazosulfapyridine | Sulphasalazine | Salazosulfapyridine | Pyralin EN | Azulfadine | Azulfidine EN | Azulfidine | Asulfidine | Colo-Pleon | Colo Pleon | Pleon | Ulcol | Sulfasalazin medac | Sulfasalazin-Heyl | Sulfasalazin Heyl | Sulfasalazine FNA | Ucine | Salazopyrin | ratio-Sulfasalazine | ratio Sulfasalazine
Chemical Information
Molecular Formula C18H14N4O5S
CAS Registry Number 599-79-1
SMILES C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Skin reaction23.03.03.013; 10.01.03.0190.000818%Not Available
Skin warm23.03.03.014--Not Available
Somnolence17.02.04.006; 19.02.05.003--
Splenomegaly01.09.02.0010.000455%Not Available
Stevens-Johnson syndrome10.01.01.045; 23.03.01.007; 12.03.01.014; 11.07.01.0050.003031%
Stomatitis07.05.06.005--
Stress19.06.02.004--Not Available
Swelling08.01.03.0150.005668%Not Available
Swelling face10.01.05.018; 08.01.03.100; 23.04.01.0180.002758%Not Available
Swollen tongue23.04.01.014; 07.14.02.003; 10.01.05.0150.001273%Not Available
Synovitis15.04.02.0010.002546%Not Available
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.0040.001515%Not Available
Tenderness08.01.08.0050.001030%Not Available
Therapeutic response decreased08.06.01.0160.000909%Not Available
Throat irritation22.12.03.029; 07.05.05.0370.000455%Not Available
Thrombocytopenia01.08.01.002--Not Available
Tinnitus04.04.01.002; 17.04.07.004--
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.0060.002273%
Trigger finger15.07.01.0050.000667%Not Available
Unresponsive to stimuli17.02.05.031--Not Available
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.0010.011578%
Uveitis10.02.01.023; 06.04.03.0030.000455%
Vascular purpura23.06.01.008; 01.01.04.007; 24.07.06.011--Not Available
Vasculitis24.12.04.027; 10.02.02.006--
Vertigo17.02.12.002; 04.04.01.003--
Vertigo positional17.02.12.004; 04.04.01.0050.000303%Not Available
Vitiligo10.04.02.004; 23.05.02.0040.000303%Not Available
The 10th Page    First    Pre   10 11 12 13 14    Next   Last    Total 15 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene